• Phone+442871675274
  • Cromore Road, Coleraine Campus

    BT52 1SA Coleraine

    United Kingdom

  • 137 Citations
  • 6 h-Index

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile


Dr Kyle Matchett completed his PhD in October 2010 at Queen’s University Belfast (QUB). His thesis examined the expression of SEPT9 splice variants in ovarian tumours from the SCOTROC trial and array CGH studies with the Institute of Cancer Research, London.

Following his PhD, Dr Matchett was appointed as a Cancer Research UK Postdoctoral Research Fellow at QUB. He discovered that estrogen metabolism is deregulated in BRCA1-deficient breast cells leading to increased production of estrogen metabolites and metabolite-induced DNA damage. Dr Matchett published his work in Cancer Research, and presented it at conferences in Montreal, London and Amsterdam. In recognition of this research, Dr Matchett was awarded the inaugural Professor John Fitzpatrick Prize by the Irish Association for Cancer Research (IACR).

Dr Matchett continued his interest in hormone signalling in breast cancer and moved to take up an EU FP7 Postdoctoral Research Fellow position focused on understanding the role of erythropoietin (EPO) in breast cancer. Based at QUB, his post involved collaboration and extensive travel with partner laboratories in Madrid, Innsbruck, Tel-Aviv, Vienna, Munich and Zurich. During this time, Dr Matchett played a key role in the development of novel EPO receptor antibodies with industrial partners Aldevron (Germany). He also led his own research which resulted in several publications.

In 2015, Dr Matchett was appointed as a Leukaemia and Leukaemia NI Postdoctoral Research Fellow following an increasing interest in haematology. His research focused on developing novel therapeutics for paediatric and adult acute myeloid leukaemia. This work has been recognised both nationally and internationally with a number of grants, invited talks and awards, including a presentation prize at XXXVI World Congress of the International Society of Haematology (2016), Little Princess Trust/Childhood Cancer and Leukaemia Group Project Grant Awards (2017, 2018) and a Novartis Fellowship Prize and Medal (2017).

In addition to his research programme, Dr Matchett completed his PGCHET in 2014 and was awarded a Fellowship of the Higher Education in 2015. He co-led a School-wide study examining postgraduate research student support, which was published in 2018.

Dr Matchett was appointed as a Lecturer at Ulster University in October 2018.

Fingerprint Dive into the research topics where Kyle Matchett is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 137 Citations
  • 6 h-Index
  • 9 Article

Tibetan PHD2, an allele with loss-of-function properties

Song, D., Navalsky, B. E., Guan, W., Ingersoll, C., Wang, T., Loro, E., Eeles, L., Matchett, K. B., Percy, M. J., Walsby-Tickle, J., McCullagh, J. S. O., Medina, R. J., Khurana, T. S., Bigham, A. W., Lappin, T. R. & Lee, F. S., 2 Jun 2020, In : Proceedings of the National Academy of Sciences of the United States of America. 117, 22, p. 12230-12238 9 p.

Research output: Contribution to journalArticle

  • 2 Citations (Scopus)

    Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo

    haggag, Y., Matchett, K., Falconer, R. A., Isreb, M., Jones, J., Faheem, A., McCarron, P. A. & El Tanani, M., 14 Feb 2019, In : Cancers. 11, 2, p. 1-21 21 p., 222.

    Research output: Contribution to journalArticle

    Open Access
  • 9 Citations (Scopus)
    2 Downloads (Pure)

    Intradermal Delivery of a Near-Infrared Photosensitizer Using Dissolving Microneedle Arrays

    Hamdan, I. M. N., Tekko, I. A., Matchett, K. B., Arnaut, L. G., Silva, C. S., McCarthy, H. O. & Donnelly, R. F., 1 Sep 2018, In : Journal of Pharmaceutical Sciences. 107, 9, p. 2439-2450 12 p.

    Research output: Contribution to journalArticle

  • 5 Citations (Scopus)

    Erythropoietin drives breast cancer progression by activation of its receptor EPOR

    Chan, K-K., Matchett, K. B., Coulter, J. A., Yuen, H-F., McCrudden, C. M., Zhang, S-D., Irwin, G. W., Davidson, M. A., Rülicke, T., Schober, S., Hengst, L., Jaekel, H., Platt-Higgins, A., Rudland, P. S., Mills, K. I., Maxwell, P., El-Tanani, M. & Lappin, T. R., 18 Mar 2017, In : Oncotarget. 8, 24, p. 38251-38263 13 p.

    Research output: Contribution to journalArticle

    Open Access
  • 12 Citations (Scopus)
    4 Downloads (Pure)

    Low-dose salinomycin induces anti-leukemic responses in AML and MLL

    Roulston, G. DR., Burt, C. L., Kettyle, L. MJ., Matchett, K. B., Keenan, H. L., Mulgrew, N. M., Ramsey, J. M., Dougan, C., McKiernan, J., Grishagin, I. V., Mills, K. I. & Thompson, A., 1 Sep 2016, In : Oncotarget. 7, 45, p. 73448-73461 14 p.

    Research output: Contribution to journalArticle

    Open Access
  • 6 Citations (Scopus)


    • 1 Examination

    PhD viva - External Examiner

    Kyle Matchett (Examiner)

    29 Jul 2020

    Activity: Examination